Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306735 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00306735 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 75 participants.
The verdict
NCT00306735, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
Interventions
- DRUG Palonosetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306735
The ClinicalTrials.gov registry entry for NCT00306735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Palonosetron is the first listed.
NCT00306735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306735 about?
NCT00306735 is a clinical study titled "Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.". The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
What is the current status of trial NCT00306735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2006-03. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00306735?
The interventions under investigation include: Palonosetron (DRUG).
Who is sponsoring clinical trial NCT00306735?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.